US company to develop peptides using adhesive patch delivery system

US-based Altea Therapeutics is working with Kai Pharmaceuticals to develop certain peptides using it

Altea is enabling KAI to receive a worldwide technology license for the further development and commercialisation of these transdermal products. Altea has agreed to fund all product development, manufacturing and commercialisation activities, and Altea may receive license payments, development and commercialization milestones and royalties on product sales from KAI.

Eric Tomlinson, president and CEO of Altea Therapeutics, said that the new partnership allows the companies to apply new technology to the new peptide drugs being developed by KAI Pharmaceuticals.